Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial.

AAPS J · 2014 · PMC4147052 · PMID 24942210

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Bevacizumab weight-normalized clearance significantly decreases with increasing baseline albumin ( p < 0.0001), and appeared to be faster in patients with lower total protein levels, higher Eastern Cooperative Oncology Group (ECOG) scores, more metastatic sites, and poorer response ( Supplement Figures ), but these correlations did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.